Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization

American Journal of Pathology

Volumn 156, Issue 2, 2000, Pages 697-707

  Ozaki, Hiroaki ^a   Seo, Man Seong ^a   Ozaki, Keiko ^a   Yamada, Haruhiko ^a   Yamada, Eri ^a   Okamoto, Naoyuki ^a   Hofmann, Francesco ^b   Wood, Jeanette M ^b   Campochiaro, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GENISTEIN; IMATINIB; MIDOSTAURIN; N [4 METHYL 3 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINO]PHENYL]BENZAMIDE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RHODOPSIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; EYE BLOOD FLOW; MOUSE; NEWBORN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; RETINOPATHY; SIGNAL TRANSDUCTION;

EID: 0033882794     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64773-6     Document Type: Article

References (25)

1. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia
2. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
3. Oxygen-induced retinopathy in the mouse
4. Variable oxygen exposure causes preretinal neovascularization in the newborn rat
5. Blindness caused by diabetic retinopathy
6. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy
7. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
8. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy
9. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases
10. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model
11. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization
12. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
13. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy
14. Essential role of growth hormone in ischemia-induced retinal neovascularization
15. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor
16. Evolution of neovascularization in mice with over-expression of vascular endothelial growth factor in photoreceptors
17. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: A new model of intraretinal and subretinal neovascularization
18. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
19. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class
20. Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation
21. A novel and potent inhibitor of VEGF receptor tyrosine kinases impairs VEGF-induced responses and tumor growth after oral administration
22. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal diseases
23. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization
24. Antagonists of integrin α-v β-3 inhibit retinal neovascularization in a murine model
25. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization